

Title (en)
THE USE OF HIV-1 INTEGRASE IN SCREENING HIV-1 DRUG CANDIDATES

Title (de)
VERWENDUNG VON HIV-1 INTEGRASE BEIM SCREENING VON POTENTIELLEN HIV-1 ARZNEISTOFFEN

Title (fr)
UTILISATION DE L'INTEGRASE DU VIH-1 DANS LE CRIBLAGE DE MEDICAMENTS CANDIDATS DIRIGES CONTRE LE VIH-1

Publication
EP 1053358 A4 20020814 (EN)

Application
EP 99905936 A 19990210

Priority
• US 9902912 W 19990210
• US 7427498 P 19980210

Abstract (en)
[origin: WO9940227A1] The present invention harnesses the roles of IN to screen drug candidates to inhibit HIV-1. The present invention uses IN mutants and fusion proteins to assess the effectiveness of a drug candidate in inhibiting a native IN function. The retrovirus integrase protein (IN) is essential for integration of the viral DNA into host cell chromosomes as well as for retroviruses in general. The ability of a drug candidate to inhibit retroviral replication utilizes a monitoring system such as a host cell culture infected with a retrovirus. After exposing the monitoring system to the drug candidate, the retroviral life cycle within the monitoring system is monitored and compared to monitoring system life cycle function of integrase mutant retrovirus. Alternatively, an integrase fusion protein of either vpr or vpx is added to a monitoring system infected with a retrovirus expressing wild-type integrase following exposure to a drug candidate. Changes in retrovirus life cycle function are monitored for suppression of a wild-type integrase function indicating retroviral replication has been comprised.

IPC 1-7
C12Q 1/70; **G01N 33/53**; **G01N 33/566**; **C12N 7/00**; **C12N 15/00**

IPC 8 full level
C07K 14/16 (2006.01)

CPC (source: EP)
C07K 14/005 (2013.01); **C07K 2319/00** (2013.01); **C12N 2740/16222** (2013.01); **C12N 2740/16322** (2013.01)

Citation (search report)
• [X] WO 9632494 A1 19961017 - UNIV ALABAMA RES FOUND [US]
• [E] WO 9949891 A1 19991007 - UNIV JEFFERSON [US]
• [XD] LIU HONGMEI ET AL: "Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Po1 precursor protein.", JOURNAL OF VIROLOGY, vol. 71, no. 10, 1997, pages 7704 - 7710, XP002195170, ISSN: 0022-538X
• [DX] FLETCHER THOMAS M III ET AL: "Complementation of integrase function in HIV-1 virions.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 16, 1997, pages 5123 - 5138, XP002195171, ISSN: 0261-4189
• [DX] WU XIAOYUN ET AL: "Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 16, 1997, pages 5113 - 5122, XP002195172, ISSN: 0261-4189
• [AD] WU XIAOYUN ET AL: "Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.", JOURNAL OF VIROLOGY, vol. 70, no. 6, 1996, pages 3378 - 3384, XP002195173, ISSN: 0022-538X
• [DA] WU X ET AL: "TARGETING FOREIGN PROTEINS TO HUMAN IMMUNODEFICIENCY VIRUS PARTICLES VIA FUSION WITH VPR AND VPX", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 6, 1 June 1995 (1995-06-01), pages 3389 - 3398, XP000608410, ISSN: 0022-538X
• See references of WO 9940227A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9940227 A1 19990812; AU 2597599 A 19990823; EP 1053358 A1 20001122; EP 1053358 A4 20020814

DOCDB simple family (application)
US 9902912 W 19990210; AU 2597599 A 19990210; EP 99905936 A 19990210